ロード中...
Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells
Resistance is one limitation of sorafenib in the treatment of hepatocellular carcinoma (HCC). Insulin-like growth factor-1 receptor (IGF-1R) is involved in cancer cell proliferation. To assess the potential synergistic antitumor effects of picropodophyllin (PPP), an IGF-1R inhibitor, HLF and PLC/PRL...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4186500/ https://ncbi.nlm.nih.gov/pubmed/25289088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2014.2484 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|